



Zocere, Inc.

GENERATION NEXT IN STROKE THERAPEUTICS



We all know someone
struck down by
STROKE.





Every 40 seconds someone in the US has a stroke.

- The second most common cause of death worldwide
- Leading cause of long-term disability in adults
- Each year, about 795,000 people suffer from stroke
- 130,000 die
- \$73.7 billion in direct/indirect costs in US in 2010





Current Therapies: Too Little Too Late

Activase (tPA) drug to dissolve clots

- Must be given within 3 hours
- 10x increased risk of hemorrhage
- Fewer than 5.2% of ischemic stroke patients received tPA in 2009

MERCI Retrieval System

- Surgical
- Not widely used

Penumbra System & Coil 400

- Surgical
- Not widely used





What if we could

PROTECT THE BRAIN

from stroke-induced damage?





Zocere Solution: An Injectable NeuroProtectant Stroke Drug

- Novel peptide sequence (STEP)
- Significant protection against ischemic stroke brain injury
- Works with or without tPA



Zocere, Inc.



IMMEDIATE STROKE THERAPY

No MRI | No neurosurgeon | No waiting





Our Technology

Proprietary STEP peptide provides neuroprotection and counteracts the damaging effects of reduced blood flow in the brain in animal models of stroke.



Zocere, Inc.



Patenting the Technology

- Patents filed by STC.UNM, reviewed by Peacock & Myers
- Option to exclusive license to patent
- International patent protection in US, Canada, Japan and EU






Here's What We've Done:

- Extensive animal testing at University of New Mexico
- Market validation study by BioXcel
- 5-year, \$1.6 million NIH grant
 - Test the effects of the peptide on long-term recovery and in stroke models with significant co-morbidities
- Partnering/funding conversations underway





Here's Where We're Going: Exit Strategy





Investment Builds

MOMENTUM





What We Need To Make It Happen

- Series B Round: (\$1.0 to \$4.0 million)
 - Continue validation of protein and research
- Attract a pharmaceutical partner
- Begin discussions with VC firms
- Right exit at right time





Here's Where You Fit In

- Series-B round \$1,000,000 (25% of the company)
- Pre-Money Valuation: \$3,000,000
 - Series B Preferred
 - \$50,000 minimum investment





Success Stories

It can be done!

Typical deals along the preclinical/IND path:

Date	Price	Company	Bought by	Type of Deal	Drug Focus
01/2014	\$290M	Sirna Therapeutics	Alnylam Pharma	Acquisition	RNAi Technology Platform
11/2013	\$228M	BeiGene	Merck Serono	License	Cancer
09/2013	\$422M	Inovio Pharma	Roche	License	Immunotherapy for Prostate Cancer and HepB
08/2013	\$540M	Compugen	Bayer	License	Cancer
07/2013	\$387M	Array BioPharma	Celgene	R&D Collaboration	Inflammatory Diseases, Cancer



Zocere Has The Leadership Team To Take Us There

Wayne Laslie, President and Chief Executive Officer

- Former COO, Myriad Genetics & Myrexis
- Over 30 years in pharmaceutical commercialization

Alan Kolod, Chief Financial Officer

- Former CFO, Future Medical Systems Group (Switzerland)
- Over 30 years in financial management and growing companies

Kenton Zavitz, PhD, Chief Science Officer

- Director, Myriad Genetics & Myrexis
- Drug development for Alzheimer's, HIV, oncology, acute pain

Adrian Hobden, PhD, Board Member

- Former CEO, Myrexis; President, Myriad Genetics; Glaxo
- Over 30 years in pharmaceutical commercialization





Let's Talk

Please direct inquiries to:

Wayne Laslie

575.737.8365

wlaslie@zocere.com

Alan Kolod

575.737.8364

akolod@zocere.com





Zocere:

BRAIN PROTECTION

for life.





Zocere, Inc.

GENERATION NEXT IN STROKE THERAPEUTICS